Becton, Dickinson and Company’s Stock Price Soars to $238.84, Marking a Robust Increase of +2.96%

Becton, Dickinson and Company (BDX)

238.84 USD +6.87 (+2.96%) Volume: 2.08M

Becton, Dickinson and Company’s stock price surged to $238.84, marking a robust session growth of +2.96% with a significant trading volume of 2.08M, despite a slight year-to-date decrease of -2.05%, highlighting BDX’s dynamic market performance.

Latest developments on Becton, Dickinson and Company

Today, Becton Dickinson and Co‘s stock price is seeing movement following the announcement of their acquisition of Edwards Lifesciences’ critical care unit for $4.2 billion. This strategic move by the company is aimed at expanding their smart connected care offerings. Edwards Lifesciences, based in Irvine, will receive $4.2 billion in cash for the sale of their critical care group. This acquisition is expected to have a significant impact on Becton Dickinson’s position in the healthcare industry, leading to investor interest and potential growth in the company’s stock value.

A look at Becton, Dickinson and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Becton Dickinson and Co has a mixed long-term outlook. The company scores moderately across Value, Dividend, and Growth factors, indicating a stable performance in these areas. However, its Resilience score is lower, suggesting potential challenges in withstanding market fluctuations. On the bright side, Becton Dickinson and Co shines in Momentum, with a high score indicating strong market momentum and positive investor sentiment.

Becton, Dickinson and Company is a global medical technology company known for its development, manufacture, and sale of medical devices, instrument systems, and reagents. With a focus on serving healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, the company plays a crucial role in advancing healthcare solutions worldwide.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma